Nuclear lamin functions and disease

Trends in Genetics

Volumn 28, Issue 9, 2012, Pages 464-471

  Butin Israeli, Veronika ^a   Adam, Stephen A ^a   Goldman, Anne E ^a   Goldman, Robert D ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

HGPS; Laminopathies; Lamins; Progerin

Indexed keywords

HETEROCHROMATIN PROTEIN 1; LAMIN; LAMIN A; LAMIN B; LAMIN C; MICRORNA; MUTANT PROTEIN; PROTEIN LAMIN B1; PROTEIN LAMIN B2; PROTEIN PROGERIN; UNCLASSIFIED DRUG;

AUTOSOMAL DOMINANT INHERITANCE; AUTOSOMAL RECESSIVE INHERITANCE; BRAIN DEVELOPMENT; BREAST CANCER; CANCER CELL CULTURE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CELL TRANSFORMATION; CELL TYPE; COLON CANCER; COLORECTAL CANCER; CONGESTIVE CARDIOMYOPATHY; DISEASE MODEL; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; DROSOPHILA; EMBRYONIC STEM CELL; EMERY DREIFUSS MUSCULAR DYSTROPHY; EXON; FAMILIAL PARTIAL LIPODYSTROPHY; GENE DOSAGE; GENE DUPLICATION; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC ANALYSIS; GERIATRIC PATIENT; HEREDITARY MOTOR SENSORY NEUROPATHY; HETEROCHROMATIN; HETEROZYGOSITY; HOUSEKEEPING GENE; HUMAN; KERATINOCYTE; KNOCKOUT MOUSE; LAMINOPATHY; LEUKODYSTROPHY; LIMB GIRDLE MUSCULAR DYSTROPHY; LIVER CELL CARCINOMA; LUNG CANCER; MANDIBULOFACIAL DYSOSTOSIS; MISSENSE MUTATION; NONHUMAN; NUCLEAR LAMINA; OVARY CANCER; PAPANICOLAOU TEST; PHENOTYPE; PLURIPOTENT STEM CELL; PREMATURE AGING; PRIORITY JOURNAL; PROGERIA; PROSTATE CANCER; PROTEIN ASSEMBLY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MICROARRAY; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; RECEPTOR DOWN REGULATION; RESTRICTIVE DERMOPATHY; REVIEW; SKIN DISEASE; UTERINE CERVIX CANCER; WERNER SYNDROME;

ANIMALS; CELL PROLIFERATION; HUMANS; LAMINS; MUTATION; NEOPLASMS; NUCLEAR LAMINA; PLURIPOTENT STEM CELLS;

MUS;

EID: 84865186799     PISSN: 01689525     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tig.2012.06.001     Document Type: Review

References (98)

1. Dittmer T.A., Misteli T. The lamin protein family. Genome Biol. 2011, 12:222.
2. Lin F., Worman H.J. Structural organization of the human gene encoding nuclear lamin A and nuclear lamin C. J. Biol. Chem. 1993, 268:16321-16326.
3. Dechat T., et al. Nuclear lamins. Cold Spring Harb. Perspect. Biol. 2010, 2:a000547.
4. Maske C.P., et al. A carboxyl-terminal interaction of lamin B1 is dependent on the CAAX endoprotease Rce1 and carboxymethylation. J. Cell Biol. 2003, 162:1223-1232.
5. Young S.G., et al. Prelamin A, Zmpste24, misshapen cell nuclei, and progeria - new evidence suggesting that protein farnesylation could be important for disease pathogenesis. J. Lipid Res. 2005, 46:2531-2558.
6. Dai Q., et al. Mammalian prenylcysteine carboxyl methyltransferase is in the endoplasmic reticulum. J. Biol. Chem. 1998, 273:15030-15034.
7. Bergo M.O., et al. Zmpste24 deficiency in mice causes spontaneous bone fractures, muscle weakness, and a prelamin A processing defect. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:13049-13054.
8. Coffinier C., et al. Direct synthesis of lamin A, bypassing prelamin a processing, causes misshapen nuclei in fibroblasts but no detectable pathology in mice. J. Biol. Chem. 2010, 285:20818-20826.
9. Ben-Harush K., et al. The supramolecular organization of the C. elegans nuclear lamin filament. J. Mol. Biol. 2009, 386:1392-1402.
10. Zackroff R.V., Goldman R.D. In vitro assembly of intermediate filaments from baby hamster kidney (BHK-21) cells. Proc. Natl. Acad. Sci. U.S.A. 1979, 76:6226-6230.
11. Kapinos L.E., et al. Characterization of the head-to-tail overlap complexes formed by human lamin A, B1 and B2 'half-minilamin' dimers. J. Mol. Biol. 2010, 396:719-731.
12. Volkova E.G., et al. Self-organization of cellular structures induced by the overexpression of nuclear envelope proteins: a correlative light and electron microscopy study. J. Electron Microsc. (Tokyo) 2011, 60:57-71.
13. Shimi T., et al. The A- and B-type nuclear lamin networks: microdomains involved in chromatin organization and transcription. Genes Dev. 2008, 22:3409-3421.
14. Sullivan T., et al. Loss of A-type lamin expression compromises nuclear envelope integrity leading to muscular dystrophy. J. Cell Biol. 1999, 147:913-920.
15. Stewart C., Burke B. Teratocarcinoma stem cells and early mouse embryos contain only a single major lamin polypeptide closely resembling lamin B. Cell 1987, 51:383-392.
16. Harborth J., et al. Identification of essential genes in cultured mammalian cells using small interfering RNAs. J. Cell Sci. 2001, 114:4557-4565.
17. Vergnes L., et al. Lamin B1 is required for mouse development and nuclear integrity. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:10428-10433.
18. Yang S.H., et al. An absence of both lamin B1 and lamin B2 in keratinocytes has no effect on cell proliferation or the development of skin and hair. Hum. Mol. Genet. 2011, 20:3537-3544.
19. Kim Y., et al. Mouse B-type lamins are required for proper organogenesis but not by embryonic stem cells. Science 2011, 334:1706-1710.
20. Shimi T., et al. The role of nuclear lamin B1 in cell proliferation and senescence. Genes Dev. 2011, 25:2579-2593.
21. Barascu A., et al. Oxidative stress induces an ATM-independent senescence pathway through p38 MAPK-mediated lamin B1 accumulation. EMBO J. 2012, 31:1080-1094.
22. Malhas A.N., Vaux D.J. Transcription factor sequestration by nuclear envelope components. Cell Cycle 2009, 8:959-960.
23. Parrinello S., et al. Oxygen sensitivity severely limits the replicative lifespan of murine fibroblasts. Nat. Cell Biol. 2003, 5:741-747.
24. Coffinier C., et al. Abnormal development of the cerebral cortex and cerebellum in the setting of lamin B2 deficiency. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:5076-5081.
25. Coffinier C., et al. Deficiencies in lamin B1 and lamin B2 cause neurodevelopmental defects and distinct nuclear shape abnormalities in neurons. Mol. Biol. Cell 2011, 22:4683-4693.
26. Coffinier C., et al. LINCing lamin B2 to neuronal migration: growing evidence for cell-specific roles of B-type lamins. Nucleus 2010, 1:407-411.
27. Yoon B.C., et al. Local translation of extranuclear lamin B promotes axon maintenance. Cell 2012, 148:752-764.
28. Jung H.J., et al. Regulation of prelamin A but not lamin C by miR-9, a brain-specific microRNA. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:E423-E431.
29. Padiath Q.S., et al. Lamin B1 duplications cause autosomal dominant leukodystrophy. Nat. Genet. 2006, 38:1114-1123.
30. Padiath Q.S., Fu Y.H. Autosomal dominant leukodystrophy caused by lamin B1 duplications a clinical and molecular case study of altered nuclear function and disease. Methods Cell Biol. 2010, 98:337-357.
31. Schuster J., et al. Genomic duplications mediate overexpression of lamin B1 in adult-onset autosomal dominant leukodystrophy (ADLD) with autonomic symptoms. Neurogenetics 2011, 12:65-72.
32. Guaraldi P., et al. Isolated noradrenergic failure in adult-onset autosomal dominant leukodystrophy. Auton. Neurosci. 2011, 159:123-126.
33. Brussino A., et al. A family with autosomal dominant leukodystrophy linked to 5q23.2-q23.3 without lamin B1 mutations. Eur. J. Neurol. 2010, 17:541-549.
34. Lin S.T., Fu Y.H. miR-23 regulation of lamin B1 is crucial for oligodendrocyte development and myelination. Dis. Model Mech. 2009, 2:178-188.
35. Brandt A., et al. The farnesylated nuclear proteins KUGELKERN and LAMIN B promote aging-like phenotypes in Drosophila flies. Aging Cell 2008, 7:541-551.
36. Worman H.J., et al. Diseases of the nuclear envelope. Cold Spring Harb. Perspect. Biol. 2010, 2:a000760.
37. Dechat T., et al. Alterations in mitosis and cell cycle progression caused by a mutant lamin A known to accelerate human aging. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:4955-4960.
38. Ragnauth C.D., et al. Prelamin A acts to accelerate smooth muscle cell senescence and is a novel biomarker of human vascular aging. Circulation 2010, 121:2200-2210.
39. Rodriguez S., Eriksson M. Low and high expressing alleles of the LMNA gene: implications for laminopathy disease development. PLoS ONE 2011, 6:e25472.
40. Rodriguez S., et al. Increased expression of the Hutchinson-Gilford progeria syndrome truncated lamin A transcript during cell aging. Eur. J. Hum. Genet. 2009, 17:928-937.
41. Olive M., et al. Cardiovascular pathology in Hutchinson-Gilford progeria: correlation with the vascular pathology of aging. Arterioscler. Thromb. Vasc. Biol. 2010, 30:2301-2309.
42. Cao K., et al. A lamin A protein isoform overexpressed in Hutchinson-Gilford progeria syndrome interferes with mitosis in progeria and normal cells. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:4949-4954.
43. Burtner C.R., Kennedy B.K. Progeria syndromes and ageing: what is the connection?. Nat. Rev. Mol. Cell Biol. 2010, 11:567-578.
44. Dreesen O., Stewart C.L. Accelerated aging syndromes, are they relevant to normal human aging?. Aging (Albany N. Y.) 2011, 3:889-895.
45. Garg A., et al. Atypical progeroid syndrome due to heterozygous missense LMNA mutations. J. Clin. Endocrinol. Metab. 2009, 94:4971-4983.
46. Taimen P., et al. A progeria mutation reveals functions for lamin A in nuclear assembly, architecture, and chromosome organization. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:20788-20793.
47. Denecke J., et al. A homozygous ZMPSTE24 null mutation in combination with a heterozygous mutation in the LMNA gene causes Hutchinson-Gilford progeria syndrome (HGPS): insights into the pathophysiology of HGPS. Hum. Mutat. 2006, 27:524-531.
48. Maraldi N.M., et al. Laminopathies and lamin-associated signaling pathways. J. Cell. Biochem. 2011, 112:979-992.
49. Lu J.T., et al. LMNA cardiomyopathy: cell biology and genetics meet clinical medicine. Dis. Model Mech. 2011, 4:562-568.
50. Marji J., et al. Defective lamin A-Rb signaling in Hutchinson-Gilford Progeria Syndrome and reversal by farnesyltransferase inhibition. PLoS ONE 2010, 5:e11132.
51. Liu Y., et al. DNA damage responses in progeroid syndromes arise from defective maturation of prelamin A. J. Cell Sci. 2006, 119:4644-4649.
52. Constantinescu D., et al. Defective DSB repair correlates with abnormal nuclear morphology and is improved with FTI treatment in Hutchinson-Gilford progeria syndrome fibroblasts. Exp. Cell Res. 2010, 316:2747-2759.
53. Liu Y., et al. Involvement of xeroderma pigmentosum group A (XPA) in progeria arising from defective maturation of prelamin A. FASEB J. 2008, 22:603-611.
54. Varela I., et al. Accelerated ageing in mice deficient in Zmpste24 protease is linked to p53 signalling activation. Nature 2005, 437:564-568.
55. Krishnan V., et al. Histone H4 lysine 16 hypoacetylation is associated with defective DNA repair and premature senescence in Zmpste24-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:12325-12330.
56. Viteri G., et al. Effect of progerin on the accumulation of oxidized proteins in fibroblasts from Hutchinson Gilford progeria patients. Mech. Ageing Dev. 2010, 131:2-8.
57. Richards S.A., et al. The accumulation of un-repairable DNA damage in laminopathy progeria fibroblasts is caused by ROS generation and is prevented by treatment with N-acetyl cysteine. Hum. Mol. Genet. 2011, 20:3997-4004.
58. Liu G.H., et al. Recapitulation of premature ageing with iPSCs from Hutchinson-Gilford progeria syndrome. Nature 2011, 472:221-225.
59. Redwood A.B., et al. A dual role for A-type lamins in DNA double-strand break repair. Cell Cycle 2011, 10:2549-2560.
60. Benson E.K., et al. Role of progerin-induced telomere dysfunction in HGPS premature cellular senescence. J. Cell Sci. 2010, 123:2605-2612.
61. Cao K., et al. Progerin and telomere dysfunction collaborate to trigger cellular senescence in normal human fibroblasts. J. Clin. Invest. 2011, 121:2833-2844.
62. Gonzalez-Suarez I., et al. Novel roles for A-type lamins in telomere biology and the DNA damage response pathway. EMBO J. 2009, 28:2414-2427.
63. Cao K., et al. Rapamycin reverses cellular phenotypes and enhances mutant protein clearance in Hutchinson-Gilford progeria syndrome cells. Sci. Transl. Med. 2011, 3:89ra58.
64. Kudlow B.A., et al. Suppression of proliferative defects associated with processing-defective lamin A mutants by hTERT or inactivation of p53. Mol. Biol. Cell 2008, 19:5238-5248.
65. Zink D., et al. Nuclear structure in cancer cells. Nat. Rev. Cancer 2004, 4:677-687.
66. Elston C.W., Ellis I.O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19:403-410.
67. Yoshida M.A., et al. Cytogenetic studies of tumor tissue from patients with nonfamilial renal cell carcinoma. Cancer Res. 1986, 46:2139-2147.
68. Murphy C.K., Beckwith J. Residues essential for the function of SecE, a membrane component of the Escherichia coli secretion apparatus, are located in a conserved cytoplasmic region. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:2557-2561.
69. Petersen I., et al. Core classification of lung cancer: correlating nuclear size and mitoses with ploidy and clinicopathological parameters. Lung Cancer 2009, 65:312-318.
70. Dechat T., et al. Nuclear lamins: major factors in the structural organization and function of the nucleus and chromatin. Genes Dev. 2008, 22:832-853.
71. Capo-chichi C.D., et al. Loss of A-type lamin expression compromises nuclear envelope integrity in breast cancer. Chin. J. Cancer 2011, 30:415-425.
72. Willis N.D., et al. Lamin A/C is a risk biomarker in colorectal cancer. PLoS ONE 2008, 3:e2988.
73. Machiels B.M., et al. Abnormal A-type lamin organization in a human lung carcinoma cell line. Eur. J. Cell Biol. 1995, 67:328-335.
74. Agrelo R., et al. Inactivation of the lamin A/C gene by CpG island promoter hypermethylation in hematologic malignancies, and its association with poor survival in nodal diffuse large B-cell lymphoma. J. Clin. Oncol. 2005, 23:3940-3947.
75. Helfand B.T., et al. Chromosomal regions associated with prostate cancer risk localize to lamin B deficient microdomains and exhibit reduced gene transcription. J. Pathol. 2012, 226:735-745.
76. Wu Z., et al. Reduced expression of lamin A/C correlates with poor histological differentiation and prognosis in primary gastric carcinoma. J. Exp. Clin. Cancer Res. 2009, 28:8.
77. Bussolati G. Proper detection of the nuclear shape: ways and significance. Rom. J. Morphol. Embryol. 2008, 49:435-439.
78. Belt E.J., et al. Loss of lamin A/C expression in stage II and III colon cancer is associated with disease recurrence. Eur. J. Cancer 2011, 47:1837-1845.
79. Foster C.R., et al. The role of lamin A in cytoskeleton organization in colorectal cancer cells: a proteomic investigation. Nucleus 2011, 2:434-443.
80. Foster C.R., et al. Lamins as cancer biomarkers. Biochem. Soc. Trans. 2010, 38:297-300.
81. Tang Y., et al. Promotion of tumor development in prostate cancer by progerin. Cancer Cell Int. 2010, 10:47.
82. Moss S.F., et al. Decreased and aberrant nuclear lamin expression in gastrointestinal tract neoplasms. Gut 1999, 45:723-729.
83. Broers J.L., et al. Nuclear A-type lamins are differentially expressed in human lung cancer subtypes. Am. J. Pathol. 1993, 143:211-220.
84. Coradeghini R., et al. Differential expression of nuclear lamins in normal and cancerous prostate tissues. Oncol. Rep. 2006, 15:609-613.
85. Sun S., et al. Circulating lamin B1 (LMNB1) biomarker detects early stages of liver cancer in patients. J. Proteome Res. 2010, 9:70-78.
86. Zhang J., et al. A human iPSC model of Hutchinson Gilford progeria reveals vascular smooth muscle and mesenchymal stem cell defects. Cell Stem Cell 2011, 8:31-45.
87. Ho J.C., et al. Generation of induced pluripotent stem cell lines from 3 distinct laminopathies bearing heterogeneous mutations in lamin A/C. Aging (Albany N. Y.) 2011, 3:380-390.
88. Koshimizu E., et al. Embryonic senescence and laminopathies in a progeroid zebrafish model. PLoS ONE 2011, 6:e17688.
89. Cohen T.V., Stewart C.L. Fraying at the edge mouse models of diseases resulting from defects at the nuclear periphery. Curr. Top. Dev. Biol. 2008, 84:351-384.
90. Yang S.H., et al. A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson-Gilford progeria syndrome mutation. J. Clin. Invest. 2006, 116:2115-2121.
91. Yang S.H., et al. Absence of progeria-like disease phenotypes in knock-in mice expressing a non-farnesylated version of progerin. Hum. Mol. Genet. 2011, 20:436-444.
92. Gordon L.B., et al. Highlights of the 2007 Progeria Research Foundation scientific workshop: progress in translational science. J. Gerontol. A: Biol. Sci. Med. Sci. 2008, 63:777-787.
93. Pereira S., et al. HGPS and related premature aging disorders: from genomic identification to the first therapeutic approaches. Mech. Ageing Dev. 2008, 129:449-459.
94. Varela I., et al. Combined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging. Nat. Med. 2008, 14:767-772.
95. Taylor F., et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst. Rev. 2011, 1:CD004816.
96. Baron R., et al. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 2011, 48:677-692.
97. Verstraeten V.L., et al. Protein farnesylation inhibitors cause donut-shaped cell nuclei attributable to a centrosome separation defect. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:4997-5002.
98. Szeverenyi I., et al. The Human Intermediate Filament Database: comprehensive information on a gene family involved in many human diseases. Hum. Mutat. 2008, 29:351-360.